Results 81 to 90 of about 11,904 (210)

Effectiveness of rivastigmine in Alzheimer's disease

, 2023
Effectiveness of rivastigmine in Alzheimer's ...
E Sellwood (13591486), J Raftery (7704848), M N Rossor (13493140), R Gray (7775780), Richard Harvey (13090974), J G Storosum (13591492), M R Trimble (13591375), A J A Elferink (13591498), C E Selai (13591372), B J Van Zwieten-Boot (13591495), M Rösler (13591489), P Bentham (13591483)   +11 more
core  

A Robust and Universal LC–MS/MS Method for Determination of N‐Nitrosodimethylamine in Pharmaceuticals Using a C30 Column

Journal of Separation Science, Volume 49, Issue 6, June 2026.
ABSTRACT Since the 2018 valsartan recall, the genotoxic impurity N‐nitrosodimethylamine (NDMA) has been frequently detected in various pharmaceuticals. Matrix variability often complicates routine testing, requiring customized analyses. We developed a universal LC–MS/MS method enabling consistent NDMA detection across diverse pharmaceuticals ...
Byungchan An, Unyong Kim, Sumin Seo, Jiyu Kim, Chohee Jeong, Woojin Jeong, Eunjin Ko, Juhyeon Kim, Hyun‐Deok Cho, Sang Beom Han   +9 more
wiley   +1 more source

Beyond the Known and Established Neurodegenerative Effects: Roles of APOE Across a Wide Spectrum of Pathophysiological Condition

MedComm, Volume 7, Issue 6, June 2026.
APOE is widely recognized for its role in neurodegeneration and cardiovascular disease, but its different genotypes also influence body composition, affecting obesity, bone density, and muscle mass, through their central role in lipid transport and metabolism.
Miriam Frosina, Samantha Maurotti, Alberto Castagna, Tiziana Montalcini, Arturo Pujia, Luca Tirinato   +5 more
wiley   +1 more source

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

Behavioural Neurology, 1999
Alzheimer’s disease (AD) is accompanied by prominent behavioural disturbances. They cause significant distress for both caregivers and patients and can play a major role in the decision to institutionalise AD patients.
Michael Rösler, Wolfgang Retz, P. Retz-Junginger, Hans Joachim Dennler   +3 more
doaj   +1 more source

Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease

Neuroprotection, Volume 4, Issue 2, Page 111-130, June 2026.
In Parkinson's disease (PD) and Alzheimer's disease (AD), various shared pathological mechanisms exist. UDCA has been shown to exert neuroprotective effects in preclinical and clinical studies. Such effects include the mitigation of neuroinflammation as well as rescue effects on mitochondrial dysfunction, oxidative stress, impaired autophagy, and ...
Ashley En Yi Chong, Andrew Octavian Sasmita, Rhun Yian Koh, Anna Pick Kiong Ling   +3 more
wiley   +1 more source

A fatal outcome after unintentional overdosing of rivastigmine patches

, 2012
BACKGROUND: Rivastigmine is an acetylcholine esterase inhibitor used in the treatment of dementia. Patches with rivastigmine for transdermal delivery have been used to increase compliance and to reduce side effects.
Jönsson, Anna K,, Hägg, Staffan, Jönsson, Anna K, Hägg, Staffan,, Lövborg, Henrik,, Lövborg, Henrik   +5 more
core   +1 more source

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson

Tijdschrift voor Gerontologie en Geriatrie
Casusbespreking van drie patie¨nten opgenomen in verband met hallucinaties bij de ziekte van Parkinson zonder dementie waarbij naast aanpassing van de anti-parkinson medicatie tevens wordt gestart met rivastigmine waardoor hallucinaties verdwenen en ...
jmp Rovers, plj Dautzenberg, jp ter bruggen   +2 more
doaj   +1 more source

Evaluation of the Phytochemical Composition, Antioxidant Activity, and Enzyme Inhibitory Potential of Salvia heldreichiana Within the Framework of Molecular Docking and CAVER Tunnel Analysis

ChemistryOpen, Volume 15, Issue 6, June 2026.
Methanolic extract of Salvia heldreichiana is characterized by HPLC and GC–MS analyses and evaluated for antioxidant and anti‐Alzheimer activities. Major phenolic compounds are identified, while molecular docking analysis supports the interaction of bioactive constituents with target enzymes, highlighting the therapeutic potential of S.
Erdi Can Aytar, Esin Çolak, Kaan Bedirhan Kahveci, Abidin Gümrükçüoğlu, Süleyman Doğu, Betül Aydın   +5 more
wiley   +1 more source

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease

, 2013
Manal Fouad Ismail,1 Aliaa Nabil ElMeshad,2 Neveen Abdel-Hameed Salem31Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo ...
ElMeshad AN, Salem NA, Ismail MF
core  

Rivastigmine enhances cell viability in neurodegenerating primary cultures.

, 2013
A: Rivastigmine is a parasympathomimetic cholinergic agent used for the treatment of mild to moderate AD. Its systematic (IUPAC) name is (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate.
Jason A. Bailey (229720), Debomoy K. Lahiri (331483), Balmiki Ray (331481), Nigel H. Greig (214075)   +3 more
core   +1 more source